Our partner is dedicated to creating life-changing T cell therapies by unleashing the untapped potential of the human immune system. Their proprietary platform technologies allow them to analyze the T cells of cancer patients with exceptional responses to immunotherapy to discover new targets and expand the reach of their therapies to other patient populations.

This critical hire built the team and led efforts to develop an autologous human TCR-engineered T-cell product manufacturing process. They played an integral part of our partner’s Technology Development and Manufacturing team, which was preparing for the clinical development of new T-cell therapy targets discovered using proprietary platform technologies.